ProBiotix Health Plc

Regulatory Filings • Oct 14, 2025

National Storage Mechanism | Additional information

RNS Number : 1884D

Probiotix Health PLC

14 October 2025

14 October 2025

ProBiotix Health plc

("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")

New Commercial Partnership in Sweden

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a commercial partnership with Sweden based RevivaBio.

ProBiotix has entered a commercial cooperation with RevivaBio, one of Sweden's fastest growing health companies, to launch a new cholesterol lowering product powered by the ProBiotix patented probiotic strain LP LDL ®. The collaboration marks an important step in RevivaBio's strategy, through new product introductions based on scientifically validated ingredients.

After an extensive evaluation of innovations in cardiometabolic health, RevivaBio selected LP LDL ® for its clinically validated ability to help manage cholesterol levels safely and effectively. RevivaBio's new product will be introduced and launched in Sweden and a number of APAC markets during Q1 2026, in a capsule dietary supplement under RevivaBio's own brand. The product will be distributed through health stores as well as through e-commerce activities. As part of the collaboration, ProBiotix will manufacture the primary finished capsules product and RevivaBio will be responsible for the final packaging of the product.

Founded in 2002 and headquartered in Uppsala, RevivaBio has become a recognised player in the Swedish health and nutrition market. The company develops, manufactures, and sells a wide range of science-based dietary supplements focused on gut health, histamine intolerance, inflammation, and immune balance. With its own modern production facility and a dedicated team, RevivaBio is known for its high-quality standards, innovation, and customer focus.

RevivaBio's portfolio includes well-known products such as DAOfood®, Daosin®, and Atrantil.

The company has built a strong reputation for customer satisfaction and trust, being recommended on Sweden's leading review platform, Reco.se, for seven consecutive years, with an average customer rating of 4.6 out of 5 from more than 700 verified reviews.

Cardiovascular disease remains one of the leading health challenges in Sweden and globally. RevivaBio aims to make a meaningful contribution to heart health by offering scientifically proven and natural solutions.

Steen Andersen, CEO of ProBiotix, commented : "The collaboration marks another important step in our ambition to further our expansion internationally. We are delighted to be working with RevivaBio to develop a new probiotic product, which we believe will prove a highly successful new offering.

"The cooperation further demonstrates the growing global demand for probiotic products that support heart health, and is expected to help further accelerate our sales growth."

Thomas Frid, General Manager of RevivaBio, added : "Partnering with ProBiotix Health and introducing LP LDL ® is a major milestone for us. We are proud to strengthen our product portfolio with a world-leading probiotic innovation.

"Together, we can make a real difference in improving heart health, both here in Sweden and abroad."

For further information, please contact:

ProBiotix Health plc	https://probiotixhealth-ir.com/
	[email protected]
Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations
Peterhouse Capital Limited Aquis Corporate Adviser and Broker
Mark Anwyl Duncan Vasey	Tel: 020 7469 0930

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

Notes to Editors:

ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.

The Company has a singular approach: discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXBIBDGDXBDGUX